{"schema_version":"secwatch.filing_event.v1","accession":"0000014272-25-000129","form_type":"8-K","ticker":"BMY","cik":"0000014272","company_name":"BRISTOL MYERS SQUIBB CO","filed_at":"2025-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.965859+00:00","generated_at":"2026-05-17T22:15:33.757880+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BMY Q2 revenue $12.3B, GAAP EPS $0.64, non-GAAP EPS $1.46; raises revenue guidance","bullets":["Revenue $12.3B, +1% YoY; Growth Portfolio $6.6B, +18% YoY (+17% ex-FX).","GAAP EPS $0.64 vs $0.83 YoY; non-GAAP EPS $1.46 vs $2.07 YoY, both hit by $(0.57) BioNTech IPRD charge.","2025 revenue guidance raised to ~$46.5B–$47.5B; non-GAAP EPS guidance updated to $6.35–$6.65.","BioNTech strategic partnership resulted in a $0.57 per share Acquired IPRD charge in Q2.","CEO cites strong Growth Portfolio execution, cost optimization, and pipeline partnerships."],"urls":{"canonical":"https://secwatch.observer/filing/0000014272-25-000129","json":"https://secwatch.observer/filing/0000014272-25-000129.json","markdown":"https://secwatch.observer/filing/0000014272-25-000129.md","text":"https://secwatch.observer/filing/0000014272-25-000129.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/14272/000001427225000129/0000014272-25-000129-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/14272/000001427225000129/bmy-20250731.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T22:15:33.757880+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}